









Markets
/
Stocks
/
nasdaq-eltx
/

Elicio Therapeutics Inc

ELTX



View Detailed Chart

8.195USD

+0.255+3.21%

Market hours （ET）Quotes delayed by 15 min

141.43MMarket Cap

LossP/E TTM



Elicio Therapeutics Inc

8.195

+0.255+3.21%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+3.21%

5 Days

+0.12%

1 Month

-3.02%

6 Months

+1.80%

Year to Date

+60.69%

1 Year

+67.93%

View Detailed Chart

TradingKey Stock Score of Elicio Therapeutics Inc

Currency: USD Updated: 2025-12-19

Key Insights

Elicio Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 151/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.50.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Elicio Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

151 / 404

Overall Ranking

279 / 4582

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

15.500

Target Price

+83.76%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Elicio Therapeutics Inc Highlights

StrengthsRisks

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -2.55, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 473.86K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.85.